• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

培氟沙星在肾功能正常和受损情况下的药代动力学。

Pharmacokinetics of pefloxacin in normal and impaired renal function.

作者信息

Höffler D, Schäfer I, Koeppe P, Sörgel F

机构信息

Städtische Kliniken Darmstadt, Medizinische Klinik III, Fed. Rep. of Germany.

出版信息

Arzneimittelforschung. 1988 May;38(5):739-43.

PMID:3166377
Abstract

Ten healthy young volunteers (mean age 28 years) and 24 patients (mean age 54 years) suffering from various degrees of chronic renal failure received an infusion of 400 mg pefloxacin (1-ethyl-6-fluoro-1, 4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid) over 30 min. The blood and urine levels of pefloxacin and of the two metabolites pefloxacin-N-oxide and norfloxacin were determined using the HPLC method. Blood levels were taken after periods of 0, 60, 120, 180, 360, 600, 720, 1440, 2880, 3360 min, and in patients suffering from renal insufficiency also after 4320 min. The urine was collected and analyzed during the periods of 0-2, 2-4, 4-10 (12) h and then in longer periods up to 72 h. In all subjects, the glomerular filtration rate (GFR, by chrome-51-EDTA) and the plasma creatinine level were determined. Effective levels against bacteria lying in pefloxacin's spectrum can be found in the plasma for about 1.5 days and in the urine for about 2.5 days. Patients suffering from chronic renal failure have pefloxacin plasma levels which beyond 24 h are higher than in healthy persons. This can be explained by both: impaired renal and extrarenal elimination. The volume of distribution of the volunteer and the patient group does not differ significantly. Therapeutic urine levels could be found in patients up to 48 h after end of infusion. Even in patients requiring regular hemodialysis, therapeutic urine levels were found up to 24 h (if urine could be produced at all). The substance therefore is a suitable remedy for urinary infections in dialysis patients as well.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

10名健康年轻志愿者(平均年龄28岁)和24名患有不同程度慢性肾衰竭的患者(平均年龄54岁)接受了在30分钟内输注400毫克培氟沙星(1-乙基-6-氟-1,4-二氢-7-(4-甲基-1-哌嗪基)-4-氧代-3-喹啉羧酸)的治疗。使用高效液相色谱法测定培氟沙星及其两种代谢产物培氟沙星-N-氧化物和诺氟沙星的血药浓度和尿药浓度。在0、60、120、180、360、600、720、1440、2880、3360分钟时采集血样,对于肾功能不全的患者,在4320分钟时也采集血样。在0-2、2-4、4-10(12)小时期间收集尿液并进行分析,然后在长达72小时的更长时间段内收集尿液并分析。在所有受试者中,测定肾小球滤过率(通过铬-51-乙二胺四乙酸测定)和血浆肌酐水平。培氟沙星对其抗菌谱内细菌的有效浓度在血浆中可维持约1.5天,在尿液中可维持约2.5天。患有慢性肾衰竭的患者培氟沙星血浆浓度在24小时后高于健康人。这可以通过肾和肾外清除功能受损来解释。志愿者组和患者组的分布容积没有显著差异。在输注结束后长达48小时的患者中可发现治疗性尿药浓度。即使是需要定期血液透析的患者,也能在长达24小时内发现治疗性尿药浓度(前提是能产生尿液)。因此,该药物也是透析患者尿路感染的合适治疗药物。(摘要截断于250字)

相似文献

1
Pharmacokinetics of pefloxacin in normal and impaired renal function.培氟沙星在肾功能正常和受损情况下的药代动力学。
Arzneimittelforschung. 1988 May;38(5):739-43.
2
Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.NXY-059(一种用于治疗急性中风的基于硝酮的自由基捕获剂)在肾功能受损受试者中的药代动力学。
Eur J Clin Pharmacol. 2002 Sep;58(6):409-15. doi: 10.1007/s00228-002-0478-x. Epub 2002 Aug 10.
3
Clinical pharmacokinetics of nimodipine in normal and impaired renal function.尼莫地平在肾功能正常和受损患者中的临床药代动力学
Int J Clin Pharmacol Res. 1984;4(5):381-4.
4
[Antibacterial activity of pefloxacin in the urine during the 7 days following a single 800 mg oral dose].单次口服800毫克培氟沙星后7天内尿液中的抗菌活性
Pathol Biol (Paris). 1989 May;37(5):406-10.
5
Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine.奈西立肽不能改善慢性心力衰竭且血清肌酐恶化患者的肾功能。
Circulation. 2004 Sep 21;110(12):1620-5. doi: 10.1161/01.CIR.0000141829.04031.25. Epub 2004 Aug 30.
6
Cystatin C measurement and its practical use in patients with various renal diseases.胱抑素C检测及其在各种肾脏疾病患者中的实际应用。
Clin Nephrol. 1997 Aug;48(2):104-8.
7
Pharmacokinetics and dose recommendations of carumonam in renal failure.
Arzneimittelforschung. 1987 Jan;37(1):65-9.
8
Evaluation of Bayesian estimation to discriminate subpopulations of patients with altered pharmacokinetics using fragmentary data: a pilot study with pefloxacin.使用片段数据评估贝叶斯估计以区分药代动力学改变的患者亚群:培氟沙星的一项初步研究
Eur J Drug Metab Pharmacokinet. 1991;Spec No 3:338-45.
9
Pharmacokinetics of ceftazidime in normal and impaired renal function.头孢他啶在肾功能正常和受损情况下的药代动力学。
Arzneimittelforschung. 1984;34(1):72-6.
10
Constant infusion clearance is an inappropriate method for accurate assessment of an impaired glomerular filtration rate.
Nephrol Dial Transplant. 1995;10(1):47-51.

引用本文的文献

1
Pefloxacin clinical pharmacokinetics.培氟沙星的临床药代动力学。
Clin Pharmacokinet. 1994 Dec;27(6):418-46. doi: 10.2165/00003088-199427060-00003.
2
Guide to drug dosage in renal failure.肾衰竭药物剂量指南。
Clin Pharmacokinet. 1988 Nov;15(5):326-54. doi: 10.2165/00003088-198815050-00005.
3
Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.培氟沙星。对其抗菌活性、药代动力学特性及治疗用途的综述。
Drugs. 1989 May;37(5):628-68. doi: 10.2165/00003495-198937050-00003.
4
Antimicrobial activity and interaction of pefloxacin and its principal metabolites. Collaborative Antimicrobial Susceptibility Testing Group.培氟沙星及其主要代谢产物的抗菌活性与相互作用。抗菌药敏试验协作组。
Eur J Clin Microbiol Infect Dis. 1989 Jun;8(6):551-6. doi: 10.1007/BF01967479.
5
Pharmacokinetics of single-dose intravenous, oral, and intraperitoneal pefloxacin in patients on chronic ambulatory peritoneal dialysis.慢性非卧床腹膜透析患者单剂量静脉注射、口服及腹腔注射培氟沙星的药代动力学
Antimicrob Agents Chemother. 1991 Jul;35(7):1492-4. doi: 10.1128/AAC.35.7.1492.
6
Pharmacokinetics of teicoplanin in hemodialysis patients.替考拉宁在血液透析患者中的药代动力学
Infection. 1991 Sep-Oct;19(5):324-7. doi: 10.1007/BF01645356.
7
Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients.与NONMEM相比,贝叶斯估计在群体药代动力学数据分析中的评估:在重症监护病房患者中应用于培氟沙星。
J Pharmacokinet Biopharm. 1992 Dec;20(6):653-69. doi: 10.1007/BF01064424.